KR20250009492A - Tyk2 억제제의 결정질 형태 및 그의 용도 - Google Patents
Tyk2 억제제의 결정질 형태 및 그의 용도 Download PDFInfo
- Publication number
- KR20250009492A KR20250009492A KR1020247041063A KR20247041063A KR20250009492A KR 20250009492 A KR20250009492 A KR 20250009492A KR 1020247041063 A KR1020247041063 A KR 1020247041063A KR 20247041063 A KR20247041063 A KR 20247041063A KR 20250009492 A KR20250009492 A KR 20250009492A
- Authority
- KR
- South Korea
- Prior art keywords
- crystalline form
- powder
- ray diffraction
- diffraction pattern
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341528P | 2022-05-13 | 2022-05-13 | |
| US63/341,528 | 2022-05-13 | ||
| US202263405577P | 2022-09-12 | 2022-09-12 | |
| US63/405,577 | 2022-09-12 | ||
| PCT/US2023/021986 WO2023220338A1 (en) | 2022-05-13 | 2023-05-12 | Crystalline forms of a tyk2 inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250009492A true KR20250009492A (ko) | 2025-01-17 |
Family
ID=86760338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247041063A Pending KR20250009492A (ko) | 2022-05-13 | 2023-05-12 | Tyk2 억제제의 결정질 형태 및 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20260209205A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4522602A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2025516683A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20250009492A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119907791A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023269081A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3253365A1 (cg-RX-API-DMAC7.html) |
| CL (1) | CL2024003456A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL317011A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024014000A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202409007A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023220338A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202428571A (zh) * | 2022-10-10 | 2024-07-16 | 美商雅盧米斯公司 | Tyk2抑制劑之晶型及其用途 |
| WO2026019902A1 (en) * | 2024-07-16 | 2026-01-22 | Alumis Inc. | Crystalline forms of a tyk2 inhibitor and uses thereof |
| WO2026128621A2 (en) * | 2024-12-12 | 2026-06-18 | Alumis Inc. | Process of making tyk2 inhibitors and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS66346B1 (sr) * | 2018-10-22 | 2025-01-31 | Alumis Inc | Inhibitori tyk2 i njihova upotreba |
-
2023
- 2023-05-12 US US18/865,480 patent/US20260209205A1/en active Pending
- 2023-05-12 KR KR1020247041063A patent/KR20250009492A/ko active Pending
- 2023-05-12 JP JP2024566809A patent/JP2025516683A/ja active Pending
- 2023-05-12 AU AU2023269081A patent/AU2023269081A1/en active Pending
- 2023-05-12 EP EP23730266.6A patent/EP4522602A1/en active Pending
- 2023-05-12 TW TW112117747A patent/TW202409007A/zh unknown
- 2023-05-12 CN CN202380052762.3A patent/CN119907791A/zh active Pending
- 2023-05-12 WO PCT/US2023/021986 patent/WO2023220338A1/en not_active Ceased
- 2023-05-12 CA CA3253365A patent/CA3253365A1/en active Pending
- 2023-05-12 IL IL317011A patent/IL317011A/en unknown
-
2024
- 2024-11-12 CL CL2024003456A patent/CL2024003456A1/es unknown
- 2024-11-12 MX MX2024014000A patent/MX2024014000A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023220338A1 (en) | 2023-11-16 |
| EP4522602A1 (en) | 2025-03-19 |
| IL317011A (en) | 2025-01-01 |
| TW202409007A (zh) | 2024-03-01 |
| MX2024014000A (es) | 2025-02-10 |
| US20260209205A1 (en) | 2026-07-23 |
| AU2023269081A1 (en) | 2024-11-28 |
| JP2025516683A (ja) | 2025-05-30 |
| CL2024003456A1 (es) | 2025-04-25 |
| CN119907791A (zh) | 2025-04-29 |
| CA3253365A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6846574B2 (ja) | スルホンアミド化合物およびその使用 | |
| TW202409007A (zh) | Tyk2抑制劑之晶型及其用途 | |
| US20250376459A1 (en) | Crystalline forms of a tyk2 inhibitor and uses thereof | |
| WO2016151304A1 (en) | Novel polymorphic form x of nilotinib dihydrochloride hydrate | |
| US20240182443A1 (en) | Polymorphic forms of compound and preparation method therefor and application thereof | |
| US20260138965A1 (en) | Crystalline forms of a tyk2 inhibitor and uses thereof | |
| US20240368185A1 (en) | Macrocyclic azolopyridines | |
| WO2026019902A1 (en) | Crystalline forms of a tyk2 inhibitor and uses thereof | |
| WO2026019908A1 (en) | Crystalline forms of a tyk2 inhibitor and uses thereof | |
| TW202610624A (zh) | Tyk2抑制劑之晶型及其用途 | |
| TW202334088A (zh) | 固體形式 | |
| CN110903291B (zh) | 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法 | |
| CN115772123A (zh) | 固体形式 | |
| HK40023760B (en) | Sulfonamide compounds and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |